trimetrexate has been researched along with Head and Neck Neoplasms in 6 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human SCC-25 squamous carcinoma cells were exposed to methotrexate, trimetrexate or PT523 at a concentration of 5 microM for 24 h along with various concentrations of etoposide or novobiocin during the final 2 h." | 1.29 | Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. ( Holden, SA; Northey, D; Robinson, MF; Rosowsky, A; Teicher, BA, 1995) |
| "Three human squamous carcinoma cell lines (FaDu, A253, and SQCC/Y1) were tested for sensitivity to methotrexate (MTX) and trimetrexate, a second generation folate antagonist in clinical trials." | 1.28 | Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. ( Bertino, JR; Chang, YM; McGuire, JJ; Pizzorno, G, 1989) |
| "Trimetrexate is a nonclassical folate antagonist." | 1.27 | Trimetrexate as a single agent in patients with advanced head and neck cancer. ( Robert, F, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holden, SA | 1 |
| Teicher, BA | 1 |
| Robinson, MF | 1 |
| Northey, D | 1 |
| Rosowsky, A | 1 |
| Haller, DG | 1 |
| Faessel, HM | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Greco, WR | 1 |
| van der Laan, BF | 1 |
| Jansen, G | 1 |
| Kathmann, I | 1 |
| Schornagel, JH | 1 |
| Hordijk, GJ | 1 |
| Pizzorno, G | 1 |
| Chang, YM | 1 |
| McGuire, JJ | 1 |
| Bertino, JR | 1 |
| Robert, F | 1 |
1 review available for trimetrexate and Head and Neck Neoplasms
| Article | Year |
|---|---|
Trimetrexate: experience with solid tumors.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials a | 1997 |
5 other studies available for trimetrexate and Head and Neck Neoplasms
| Article | Year |
|---|---|
Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cell Line; Cell Survival; D | 1995 |
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; D | 1999 |
Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedules.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Drug Resistance; Head and | 1991 |
Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Resistance; Head and Neck Neoplasms; Humans; M | 1989 |
Trimetrexate as a single agent in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quin | 1988 |